- Home
- ORKA vs OUT Comparison
ORKA vs OUT Comparison
Compare ORKA & OUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORKA | OUT |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.1B |
| IPO Year | 1997 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ORKA | OUT |
|---|---|---|
| Price | $79.92 | $30.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $155.00 | $38.00 |
| AVG Volume (30 Days) | 985.1K | ★ 1.6M |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 4.40% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | ★ $1,831,700,000.00 |
| Revenue This Year | N/A | $9.12 |
| Revenue Next Year | N/A | $2.62 |
| P/E Ratio | ★ N/A | $55.79 |
| Revenue Growth | N/A | ★ 0.04 |
| 52 Week Low | $24.88 | $16.97 |
| 52 Week High | $115.52 | $34.96 |
Technical Indicators
Market Signals| Indicator | ORKA | OUT |
|---|---|---|
| Relative Strength Index (RSI) | 37.00 | 66.10 |
| Support Level | $54.31 | $30.14 |
| Resistance Level | $97.45 | $30.84 |
| Average True Range (ATR) | 4.22 | 0.59 |
| MACD | -0.39 | 0.33 |
| Stochastic Oscillator | 20.72 | 98.55 |
Price Performance
Historical ComparisonAbout ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
About OUT OUTFRONT Media Inc.
Outfront Media Inc is a real estate investment trust involved in the ownership of advertising space on its portfolio of billboards and transit displays. The company has two reportable operating segments: Billboard and Transit. It derives maximum revenue from Billboard Segment. The company geographically operates in United States and Canada, of which United States derive maximum revenue.